MA51914A - Formes posologiques et procédés pour obtenir du bupropion énantiomériquement enrichi ou pur - Google Patents

Formes posologiques et procédés pour obtenir du bupropion énantiomériquement enrichi ou pur

Info

Publication number
MA51914A
MA51914A MA051914A MA51914A MA51914A MA 51914 A MA51914 A MA 51914A MA 051914 A MA051914 A MA 051914A MA 51914 A MA51914 A MA 51914A MA 51914 A MA51914 A MA 51914A
Authority
MA
Morocco
Prior art keywords
methods
dosage forms
enantiomerically enriched
pure bupropion
obtaining enantiomerically
Prior art date
Application number
MA051914A
Other languages
English (en)
Inventor
Herriot Tabuteau
Original Assignee
Axsome Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axsome Therapeutics Inc filed Critical Axsome Therapeutics Inc
Publication of MA51914A publication Critical patent/MA51914A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA051914A 2018-02-23 2019-02-25 Formes posologiques et procédés pour obtenir du bupropion énantiomériquement enrichi ou pur MA51914A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862634718P 2018-02-23 2018-02-23
US201962794469P 2019-01-18 2019-01-18
US201962809480P 2019-02-22 2019-02-22

Publications (1)

Publication Number Publication Date
MA51914A true MA51914A (fr) 2020-12-30

Family

ID=67688503

Family Applications (1)

Application Number Title Priority Date Filing Date
MA051914A MA51914A (fr) 2018-02-23 2019-02-25 Formes posologiques et procédés pour obtenir du bupropion énantiomériquement enrichi ou pur

Country Status (19)

Country Link
EP (1) EP3755312A4 (fr)
JP (3) JP2021513998A (fr)
KR (3) KR20240091043A (fr)
CN (2) CN120827545A (fr)
AU (3) AU2019223187B2 (fr)
BR (1) BR112020017179A2 (fr)
CA (1) CA3092076A1 (fr)
CL (1) CL2020002166A1 (fr)
CR (1) CR20200415A (fr)
EC (1) ECSP20060179A (fr)
IL (2) IL276871B2 (fr)
MA (1) MA51914A (fr)
MX (2) MX2020008704A (fr)
MY (1) MY202993A (fr)
NI (1) NI202000056A (fr)
NZ (1) NZ767378A (fr)
PE (1) PE20211752A1 (fr)
SG (1) SG11202008056SA (fr)
WO (1) WO2019165379A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL276871B2 (en) * 2018-02-23 2024-11-01 Axsome Therapeutics Inc Dosage forms and methods for enantiomerically enriched or pure bupropion
US11660274B2 (en) 2018-09-20 2023-05-30 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
US11291639B2 (en) 2018-09-20 2022-04-05 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
US11660273B2 (en) 2018-09-20 2023-05-30 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
WO2021055124A1 (fr) * 2019-09-20 2021-03-25 Axsome Therapeutics, Inc. Formes posologiques et procédés pour la formation de bupropion énantiomériquement enrichi ou pur
US20250073188A1 (en) 2020-06-05 2025-03-06 Antecip Bioventures Ii Llc Compounds and combinations thereof for treating neurological and psychiatric conditions
US11717518B1 (en) 2022-06-30 2023-08-08 Antecip Bioventures Ii Llc Bupropion dosage forms with reduced food and alcohol dosing effects
US12156914B2 (en) * 2022-06-30 2024-12-03 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising bupropion and cysteine
US12036191B1 (en) 2022-06-30 2024-07-16 Antecip Bioventures Ii Llc Treatment of poor metabolizers of dextromethorphan with a combination of bupropion and dextromethorphan
US11730706B1 (en) 2022-07-07 2023-08-22 Antecip Bioventures Ii Llc Treatment of depression in certain patient populations
WO2025259728A1 (fr) * 2024-06-13 2025-12-18 Antecip Bioventures Ii Llc Composés et combinaisons de ceux-ci pour le traitement d'affections neurologiques et psychiatriques

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1051166A1 (fr) * 1998-01-29 2000-11-15 Sepracor, Inc. Utilisations pharmaceutiques de (+)-bupropion optiquement pur
US6337328B1 (en) * 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use
WO2005016318A1 (fr) * 2003-08-08 2005-02-24 Biovail Laboratories Inc. Comprime d'hydrochlorure de bupropion a liberation modifiee
WO2012118562A1 (fr) * 2011-03-02 2012-09-07 Rhine Pharmaceuticals, Llc Compositions et méthodes de traitement de la dépression, du trouble de l'hyperactivité avec déficit de l'attention et d'autres troubles du système nerveux central au moyen de nouveaux composés de bupropione, et procédés de production et d'utilisation de nouveaux composés de bupropione et de formulations associées
US10080727B2 (en) * 2013-11-05 2018-09-25 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US9198905B2 (en) * 2013-11-05 2015-12-01 Antecip Bioventures Ii Llc Compositions and methods for reducing dextrorphan plasma levels and related pharmacodynamic effects
US9474731B1 (en) * 2013-11-05 2016-10-25 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
WO2015095713A1 (fr) * 2013-12-20 2015-06-25 Deuterx, Llc Méthodes pour traiter des troubles neurologiques ou d'autres troubles au moyen de bupropion enrichi en deutérium énantiopure
IL276871B2 (en) * 2018-02-23 2024-11-01 Axsome Therapeutics Inc Dosage forms and methods for enantiomerically enriched or pure bupropion

Also Published As

Publication number Publication date
KR20210003091A (ko) 2021-01-11
IL276871B1 (en) 2024-07-01
CR20200415A (es) 2021-02-03
IL276871B2 (en) 2024-11-01
CN120827545A (zh) 2025-10-24
AU2019223187B2 (en) 2022-07-28
CL2020002166A1 (es) 2020-10-23
JP2022153638A (ja) 2022-10-12
IL276871A (en) 2020-10-29
IL313368A (en) 2024-08-01
EP3755312A4 (fr) 2022-03-16
NI202000056A (es) 2021-01-11
AU2019223187A1 (en) 2020-09-17
JP2021513998A (ja) 2021-06-03
CA3092076A1 (fr) 2019-08-29
JP2024075655A (ja) 2024-06-04
KR20240091043A (ko) 2024-06-21
CN112087999A (zh) 2020-12-15
BR112020017179A2 (pt) 2020-12-22
WO2019165379A1 (fr) 2019-08-29
ECSP20060179A (es) 2020-12-31
SG11202008056SA (en) 2020-09-29
AU2022204521A1 (en) 2022-07-21
AU2022204521B2 (en) 2024-09-05
MX2023009281A (es) 2023-08-17
KR20230075531A (ko) 2023-05-31
AU2024205858A1 (en) 2024-09-05
NZ767378A (en) 2024-03-22
EP3755312A1 (fr) 2020-12-30
PE20211752A1 (es) 2021-09-06
MX2020008704A (es) 2020-12-07
MY202993A (en) 2024-05-31

Similar Documents

Publication Publication Date Title
MA51914A (fr) Formes posologiques et procédés pour obtenir du bupropion énantiomériquement enrichi ou pur
EP3847818A4 (fr) Codeur vidéo, décodeur vidéo et procédés correspondants
EP3987794A4 (fr) Codeur, décodeur et procédés correspondants
MA71705A (fr) Substances et procédés pour le traitement d'hémoglobinopathies
EP3861743A4 (fr) Décodeur vidéo et procédés
MA50849A (fr) Substances et procédés pour le traitement d'hémoglobinopathies
EP4070549A4 (fr) Codeur, décodeur et procédés et dispositifs correspondants
EP3975717C0 (fr) Procédé et composition de traitement de l'eau
EP3556222C0 (fr) Système et procédé de production d'un flux de sucre
EP3552834A4 (fr) Plaque de trame et son procédé de fabrication
EP3532042A4 (fr) Procédés d'amélioration de la synaptogenèse et de la neuritogenèse
EP3864715A4 (fr) Substrat d'affichage, appareil d'affichage et procédé de fabrication de substrat d'affichage
EP3710422C0 (fr) Procédé de préparation d'amines et d'amides de cyclobutane énantiomériquement et diastéréomériquement enrichis
EP4026337A4 (fr) Codeur, décodeur et procédés correspondants
EP3461088A4 (fr) Procédé et appareil permettant de déterminer la qualité vidéo, ainsi que procédé et appareil permettant de localiser un défaut de réseau
EP3982633A4 (fr) Codeur vidéo, décodeur vidéo et procédé correspondant
EP4070551A4 (fr) Codeur, décodeur et procédés correspondants
EP3960868A4 (fr) Acide polyhydroxybutanoïque et son procédé de production
EP3868110A4 (fr) Encodeur, décodeur et procédés d'adaptation de filtre de dégroupage correspondants
EP3527191A4 (fr) Matériau composite de résine dentaire, procédé de production de matériau composite de résine dentaire, et résine de polyaryléthercétone pour produire un matériau composite de résine dentaire
EP3781137A4 (fr) Granule probiotique résistant à l'humidité et ses procédés de production
EP3896974A4 (fr) Codeur vidéo, décodeur vidéo et procédé correspondant
EP4076881C0 (fr) Dispositif pour la fabrication de blocs de béton
EP3837845A4 (fr) Codeur vidéo, décodeur vidéo et procédés correspondants
EP3686306A4 (fr) Tôle d'acier, et procédé de fabrication de celle-ci